HLA-E and neoplasm: Moreover, and different than MHC class Ia molecules, HLA-E is resistant to HIV Nef-mediated downregulation, rendering HLA-E a good candidate as an antigen-presenting molecule for the formulation of a peptide-based subunit vaccine for immunotherapy in infectious diseases or tumour immunology (7, 15, 16).